On February 06, 2026 Morgan Stanley maintained an Underweight BMY analyst rating for Bristol-Myers Squibb Company and raised its price target to $40. This action keeps Morgan Stanley’s stance cautious while nudging fair value higher. The move follows Bristol-Myers Squibb’s recent Q4 2025 report and reflects updated product and pipeline assumptions. Investors should note the direct link between analyst stance and near-term stock reaction.
BMY analyst rating: Morgan Stanley action and price target
Morgan Stanley on February 06, 2026 maintained an Underweight rating on BMY and raised its price target to $40 from $37. The report was summarized by TheFly and notes revised assumptions that lift fair value while keeping a cautious recommendation. See the Morgan Stanley note summary on TheFly.
BMY analyst rating: What ‘Maintained Underweight’ means for investors
A maintained Underweight rating signals Morgan Stanley expects BMY to underperform peers or the sector in the near term. Investors should treat the retained rating as a signal to weigh risk tolerance and holding horizon against the new $40 price target. The rating does not forbid long positions but flags cautious allocation for core portfolios.
BMY analyst rating: Historical analyst coverage and recent catalysts
Analyst coverage of Bristol-Myers Squibb Company has varied across firms and cycles, driven by quarterly results and pipeline news. The recent Q4 2025 earnings call, published three days ago, is a key catalyst that prompted Morgan Stanley’s review. For full context on the earnings call see Seeking Alpha.
BMY analyst rating: Market impact and stock reaction
After the Morgan Stanley note the stock moved 0.9% or $0.55 in the reported window. With a market capitalization of $126,145,436,318 investors should expect analyst notes to influence flows, but not always change long-term fundamentals. Short-term trading often follows rating headlines and target changes more than strategic fundamentals.
BMY analyst rating: Investor implications and next steps
Investors should compare the $40 price target to their own models and to peer valuations. A maintained Underweight from Morgan Stanley suggests trimming exposure if you target outperformance. Long-term holders should monitor pipeline updates, guidance revisions, and subsequent analyst reactions. For a full stock profile visit our Meyka page for BMY at Meyka.
Final Thoughts
The Morgan Stanley action on February 06, 2026 keeps a cautious tone for Bristol-Myers Squibb Company by maintaining an Underweight BMY analyst rating while raising the price target to $40. The change tightens fair value but leaves the recommendation conservative. Short-term investors may react to the 0.9% move and the $0.55 price swing, while longer-term holders should weigh pipeline developments and upcoming guidance. Meyka AI rates BMY with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guarantees and we are not financial advisors. Use the rating and the $40 target as inputs, not final decisions.
FAQs
What precisely did Morgan Stanley change in the BMY analyst rating on Feb 06, 2026?
Morgan Stanley maintained an Underweight BMY analyst rating on February 06, 2026 and raised its price target to $40 from $37. The firm kept its cautious recommendation while increasing its fair-value estimate.
How should I interpret the maintained Underweight for Bristol-Myers Squibb Company?
A maintained Underweight means Morgan Stanley expects BMY to underperform peers near term. It suggests careful position sizing and that investors review valuation versus the updated $40 target before trading or rebalancing.
Did the Morgan Stanley note move BMY stock and by how much?
Yes. The note corresponded with a 0.9% move, equal to $0.55 in the reported window. Market-cap context is $126,145,436,318, so price moves reflect headline sensitivity more than instant changes in fundamentals.
What does Meyka AI recommend after this BMY analyst rating update?
Meyka AI provides data and a proprietary grade; we rate BMY B+. Use the BMY analyst rating, the $40 target, and your own risk profile to decide. These data points are informative, not investment advice.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
